ERASCA INC. Share Price Today: Live Updates & Key Insights

ERASCA INC. share price today is $14.52, up -4.33%. The stock opened at $15.37 against the previous close of $15.26, with an intraday high of $15.45 and low of $14.59.

ERASCA INC. Share Price Chart

ERASCA INC.

us-stock
To Invest in {{usstockname}}
us-stock

ERASCA INC. Share Price Performance

$14.52 -0.0433(-4.33%) ERAS at 23 Mar 2026 12:54 PM Biotechnology
Lowest Today 14.59
Highest Today 15.45
Today’s Open 15.37
Prev. Close 15.26
52 Week High 16.41
52 Week Low 1.01
Day’s Range: Low 14.59 High 15.45
52-Week Range: Low 1.01 High 16.41
1 day return -
1 Week return +8.14
1 month return +11.96
3 month return +300.54
6 month return +717.92
1 year return +876.58
3 year return +400.85
5 year return -15.01
10 year return -

ERASCA INC. Institutional Holdings

Frazier Life Sciences Management, L.P. 7.34

T. Rowe Price Investment Management,Inc. 6.54

VR Adviser, LLC 5.77

Logos Global Management LP 4.89

BlackRock Inc 4.87

Suvretta Capital Management, LLC 4.68

Paradigm Biocapital Advisors LP 4.57

Vanguard Group Inc 4.14

ARCH VENTURE CORP 3.57

Vivo Capital, LLC 3.00

Siren, L.L.C. 2.83

Vanguard Total Stock Mkt Idx Inv 2.65

5AM Venture Management, LLC 1.75

Geode Capital Management, LLC 1.59

T. Rowe Price Small-Cap Value 1.38

T. Rowe Price Small-Cap Stock 1.37

iShares Russell 2000 ETF 1.36

State Street Corp 1.30

Affinity Asset Advisors, LLC 1.26

Spruce Street Capital LP 1.26

T. Rowe Price US Small-Cap Core Equity 0.98

T. Rowe Price U.S. SC Value Eq Tr-D 0.93

Vanguard Institutional Extnd Mkt Idx Tr 0.82

JPMorgan Chase & Co 0.82

The Goldman Sachs Group Inc 0.81

T. Rowe Price Instl Small-Cap Stock 0.75

Millennium Management LLC 0.72

State Street® SPDR® S&P® Biotech ETF 0.70

Soleus Capital Management, L.P. 0.70

T. Rowe Price US Smlr Coms Eq A 0.69

Fidelity Small Cap Index 0.55

iShares Russell 2000 Value ETF 0.48

T. Rowe Price U.S. SC Core Eq Tr-D 0.45

Fidelity Extended Market Index 0.40

iShares Biotechnology ETF 0.39

Schwab US Small-Cap ETF™ 0.37

State St Russell Sm/Mid Cp® Indx SL Cl I 0.35

Victory Pioneer Select Mid Cap Growth A 0.29

Vanguard Russell 2000 ETF 0.27

BlackRock Health Sciences Opps Inv A 0.23

ERASCA INC. Market Status

Strong Buy: 5

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

ERASCA INC. Fundamentals

Market Cap 4537.67 M

PB Ratio 13.9547

PE Ratio 0.0

Enterprise Value 4308.74 M

Total Assets 396.15 M

Volume 17307587

ERASCA INC. Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-230591000 -230.6M, FY22:-238160000 -238.2M, FY21:-150090000 -150.1M, FY20:-173069000 -173.1M, FY19:-10737000 -10.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-787000 -0.8M, Q1/2025:-822000 -0.8M, Q3/2024:null 0.0M, Q2/2024:-1100000 -1.1M

Quarterly Net worth Q3/2025:-30612000 -30.6M, Q2/2025:-33876000 -33.9M, Q1/2025:-30966000 -31.0M, Q3/2024:-31200000 -31.2M, Q2/2024:-63201000 -63.2M

About ERASCA INC. & investment objective

Company Information Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 103

Industry Biotechnology

CEO Dr. Jonathan E. Lim M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ERASCA INC. FAQs

What is the share price of ERASCA INC. today?

The current share price of ERASCA INC. is $14.52.

Can I buy ERASCA INC. shares in India?

Yes, Indian investors can buy ERASCA INC. shares by opening an international trading and demat account with Motilal Oswal.

How to buy ERASCA INC. shares in India?

You can easily invest in ERASCA INC. shares from India by:

Can I buy fractional shares of ERASCA INC.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ERASCA INC.?

ERASCA INC. has a market cap of $4537.67 M.

In which sector does ERASCA INC. belong?

ERASCA INC. operates in the Biotechnology sector.

What documents are required to invest in ERASCA INC. stocks?

To invest, you typically need:

What is the PE and PB ratio of ERASCA INC.?

The PE ratio of ERASCA INC. is N/A and the PB ratio is 13.95.